Reason: The group split in a week that crushed growth: $AMGN (up 4.25%) and $TMO (up 4.86%) rose into new strength and sit within 3.3% and 2.0% of their highs in intact trends, while $MRNA fell 7.82% on Friday, a week after its 52-week high, and $CRSP lost its 200-day on a negative year. MarketWatch described big pharma closing near record highs on October 15 as the tech selloff pushed investors toward safer bets; Friday's single-name moves have no cause on file.

Price/RSI Table

As of 2026-10-16. Status reads the 200-day trend first and RSI second; Action is a trend-hold lens: an extended name is never an entry, and a name below its 200-day with a negative year is not a dip.

What Changed Since 2026-10-09

• MRNA: down 7.82% on Friday and 3.11% on the week, after closing October 9 at its 52-week high. RSI fell from above 70 to 61.7 and the stock is now 10.02% under its high, still 181.7% above its 200-day ($77.40) on a +703.28% year (up 49.71% on the month). Cause not on file: its news was last pulled October 9, so news was not pulled for this week; a Form 4 filing dated October 16 is on file, unread. It moves from extended to cooling.
• AMGN: up 4.25% on the week to RSI 62.5 and 3.25% under its high, 17.2% above its 200-day ($368.90) on a +46.21% year, in a 10.2-week base with a $447.03 pivot above. News was last pulled October 7; cause not on file. MarketWatch's October 15 note on big pharma at record highs names AbbVie, Lilly and Gilead, not Amgen.
• TMO: up 4.86% to RSI 64.0 and 1.99% under its high, 26.1% above its 200-day ($547.32) on a +28.54% year; a 7.2-week base with a $704 pivot. It is scheduled to report October 21 (provider date), the first read on tool orders.
• VRTX: down 2.03% on the week, a weak short-term trend, RSI 43.8; 5.0% above its 200-day ($475.90) on a +22.3% year, 10.8% under its high. A 16.4-week base with a $560.25 pivot has not been tested. News was last pulled October 8; cause not on file.
• CRSP: down 7.75% on the week and 4.41% on Friday to RSI 39.2. It was 0.3% above its 200-day a week ago and is now 7.3% under it ($53.11) on a −28.03% year with alpha −43.56 points: the broken one in the group. The October 9 report put insider buying at +$26.6M; that figure was not refreshed this week. News pulled October 15 holds quote pages only; two Form 4 filings dated October 15 are on file, unread.
• Group read: the biotech scan's wider list gave back the October 9 recovery (the XBI fund fell 6.15% on the week) while large-cap pharma held: Lilly rose 6.59% and Regeneron 5.92% (biotech scan, October 16). No entrants or dropouts since October 9.

Watch

Thermo Fisher's October 21 report is the group's next dated test; AMGN and TMO holding their bases above the 200-day is the constructive setup, and a close back above CRSP's 200-day ($53.11) is the only thing that changes its read. MRNA needs a flag after the drop before it is anything but a cooling momentum name.

Sources

• Tape data (price, RSI, returns, one-year change, distance to the 200-day, base pivots): pre-computed summaries as of the 2026-10-16 settled close, summaries (Massive/Polygon).
• Prior edition (format and roster only): 2026-10-09-biotech; insider figure from the October 9 Form 4 net-flow report as carried in 2026-10-16-insider-scan (not refreshed).
• Event checks: research/stock-events/ (Thermo Fisher October 21 report scheduled; nothing else dated for these names), research/capture/ for October 12–16 (Form 4 filings for Moderna and CRISPR; no article headline or excerpt names these companies, and the only social captures are an ETF-holdings post listing Vertex and Amgen and a search stub for Moderna), the 2026-10-12 through 2026-10-15 market briefs under research/issues/; news receipts under stocks/news/latest.json` (TMO pulled 2026-10-15; CRSP 2026-10-15; VRTX 2026-10-08; AMGN 2026-10-07; MRNA 2026-10-09).
• Primary link: MarketWatch, Big pharma stocks close near all-time highs as tech selloff pushes investors toward safer bets, October 15 — https://www.marketwatch.com/story/big-pharma-stocks-near-all-time-highs-as-tech-selloff-pushes-investors-toward-safer-bets-0a5d5d07.